Ozem­pic sales surge could con­tin­ue in­to 2024, re­searchers say

No­vo Nordisk’s di­a­betes treat­ment Ozem­pic could be the drug in­dus­try’s sec­ond-high­est sell­er in 2024, ac­cord­ing to Eval­u­ate’s lat­est fore­cast, as an­a­lysts and physi­cians sig­nal the be­gin­ning of a new era for weight man­age­ment.

The fore­cast ex­pects Ozem­pic to gen­er­ate near­ly $12.4 bil­lion in 2023. If the mar­ket re­search firm’s pre­dic­tions are cor­rect, the GLP-1 treat­ment will rank fifth among this year’s top-sell­ing drugs af­ter not even en­ter­ing the top 10 in 2022. No­vo’s obe­si­ty and di­a­betes care sales have sky­rock­et­ed in re­cent months, up 39% in Q2 2023 com­pared to Q2 2022, ac­cord­ing to the com­pa­ny’s lat­est earn­ings re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER